INTRODUCTION
Histiocytic sarcoma (HS), formerly termed true histiocytic lymphoma, is a rare malignant neoplasm showing morphologic and immunophenotypic features of mature histiocytes. [1] [2] [3] First introduced in 1970, 4 the term histiocytic sarcoma had been broadly used in many cases of hematolymphoid neoplasms with an epithelioid or histiocytoid morphology, including many misdiagnosed as large B-cell lymphoma and anaplastic large cell lymphoma, before the advent of immunohistochemistry. Since the exclusion of histologic mimics and the confirmation of its histiocytic origin, bona fide cases of HS have become rare. 2 Despite its unknown etiology, HS has been associated with germ cell tumors 5 and hematolymphoid malignancies (particularly B-cell lymphomas). [6] [7] [8] The 2008 World Health Organization (WHO) classification 3 and the most recent 2016 update/revision 1 recognize a subset of HS with immunoglobulin heavy chain (IGH) gene and T-cell receptor gene rearrangements, most of which is considered to be transdifferentiated from other hematopoietic lineages. 1, 2 HS affects people of all ages but mainly adults. It often presents in lymph nodes, skin, and other extranodal sites, including the gastrointestinal tract, superficial and deep soft tissue, lungs, and nasal cavity. Histologically, HS shows epithelioid and pleomorphic cells with abundant eosinophilic cytoplasm in a prominent inflammatory background; it mimics other epithelioid neoplasms such as lymphomas with a large cell morphology, carcinoma, melanoma, and certain sarcomas. Because of its aggressive nature, the difficulty of the diagnosis, and the lack of a specific therapy, the prognosis for patients with HS is often poor. 9, 10 Patients with extranodal disease often undergo diagnostic fine-needle aspiration (FNA). Although the histologic features of HS are established, its FNA cytology has been limited to a few case reports. [11] [12] [13] [14] [15] [16] This study evaluates the FNA cytomorphology of 8 cases of HS in 6 patients along with clinical, histopathologic, immunophenotypic, and (in 4 cases) molecular characterization. Cytomorphologic clues and diagnostic markers leading to the diagnosis of this rare and aggressive entity are emphasized. The implications of molecular genetic findings, including recurrent alterations of lysine methyltransferase 2D (KMT2D)/ mixed-lineage leukemia 2 (MLL2), in HS are discussed.
MATERIALS AND METHODS
This study was performed with the approval of the institutional review board at our institution (institutional review board protocol 2015P002323/BWH). A search of pathology archives, including in-house and consultation files from 2005 to 2015, for cases of HS sampled by FNA yielded 8 cases from 6 patients. All FNA biopsies were performed with 22-to 25-gauge needles under image guidance. Alcohol-fixed, Papanicolaou-stained smears were prepared in all 8 cases along with paired air-dried, modified Romanowsky-stained smears in 6 cases. Cell block preparations were available in 5 cases from 5 patients. Concurrent core-needle biopsies were reviewed for 5 cases from 4 patients along with 1 subsequent excisional biopsy for 1 case and surgical resections for 4 cases from 3 patients. Cytologic, histopathologic, and clinical features of HS in 6 case reports [11] [12] [13] [14] [15] [16] were also reviewed.
Immunohistochemistry was performed on 4-lmthick sections from formalin-fixed, paraffin-embedded blocks, including 3 FNA cell blocks, 5 core-needle biopsies, 1 excisional biopsy, and 3 surgical resections. The following antibodies were used (the antigen retrieval method, dilution, and antibody clone are shown in parentheses): CD68 (protease digestion at 378C, 1:500, and KP1; Dako, Carpinteria, Calif), CD163 (pressure-cooker heat in a 0.01 M citrate buffer at pH 6.0, 1:250, and 10D6; Leica Biosystems, Mount Waverley, VIC, Australia), PU.1 (pressurecooker heat in a 0.01 M citrate buffer at pH 6.0, 1:100, and G148-74; BD Biosciences, San Diego, Calif), S100 protein (no antigen retrieval, 1:1000, and Z0311; Dako), and CD31 (protease digestion at 378C, 1:30, and JC70A; Dako). Appropriate positive and negative controls were used throughout the study. Immunohistochemical stains were interpreted as positive if staining was present in at least 5% of the tumor cells.
Targeted-exome next-generation sequencing (NGS) of 3 tumor resection samples (cases 1, 4A/4B, and 6) was performed with a published OncoPanel protocol at the Center for Advanced Molecular Diagnostics at our institution. 17 Briefly, DNA (at least 50 ng/lL) was isolated from Individual variants were manually reviewed and interpreted on the basis of the tumor percentage, read depth, alteration complexity, and evidence for associated copy-number alterations. In addition, for a tumor resection sample (case 2), targeted-exome NGS was performed with the FoundationOne assay (Foundation Medicine, Cambridge, Mass), 22 which assayed 405 cancer-associated genes and introns of 31 genes for structural rearrangements; however, no copynumber variant data were available.
RESULTS

Clinical Findings
The clinical characteristics of the 6 patients in our cohort and 6 published case reports [11] [12] [13] [14] [15] [16] are summarized in 7 One patient presented with a nasal sinus mass and a palpable neck mass (case 6). At presentation, the tumor size ranged from 0.8 to 9.1 cm (median, 4.5 cm). Four of the 6 patients had a known history of hematolymphoid malignancy: low-grade follicular lymphoma (FL; cases 1 and 4A/4B), blastoid mantle cell lymphoma (case 3), and multiple myeloma (case 5). The tumor was pretreated by combined radiotherapy and chemotherapy in 3 cases (2, 3, and 4B) and by radiotherapy alone in 1 case (4A). In all 3 cases with a known history of HS before the FNA procedure (cases 2, 3, and 4B), the diagnosis of HS was suggested by the cytopathologist, in 1 case even without a concurrent core biopsy (case 3). However, in the remaining 5 cases for which FNA with or without concurrent core-needle biopsies was used as an initial diagnostic tool, the diagnosis of HS was made after extensive immunohistochemical workups in only 2 concurrent core biopsies in conjunction with the FNA cytology (cases 4A
and 5B). The initial diagnoses proposed in the other 3 FNA-only cases included "suspicious for non-small cell carcinoma" in a lung mass (case 1; the concurrent core was nondiagnostic), "atypical cells of undetermined significance" in a retroperitoneal mass (case 5A), and "poorly differentiated malignant epithelioid neoplasm" in a neck mass (case 6), whereas the subsequent diagnosis of HS was made on the basis of a lung lobectomy (case 1), repeated FNA/ core-needle biopsy (case 5B), and pyriform sinus mass excisional biopsy (case 6). Clinical follow-up was available for 5 of 6 patients: One was alive with no evidence of disease 15 months after surgical resections for both the primary tumor in the lung and a metastatic tumor in the adrenal gland (case 1), and 4 died of disease 14 to 19 months after the initial diagnosis of HS. The imaging features of 2 extranodal HS cases (cases 4 and 5) were previously reported. 23 
Cytologic Features
Cytomorphologic features of the 8 cases of HS sampled by FNA in this study along with the 6 previous case reports [11] [12] [13] [14] [15] [16] are summarized in Table 2 . In our series, cytologic smears were variably cellular: moderately cellular in 5 cases, hypocellular in 2 cases, and hypercellular in 1 case.
Although the proportions of cell clusters versus dispersed cells varied among the 8 cases, the dispersed pattern predominated and accounted for 70% to 100% of the total cellularity in 7 cases. All cases showed a rich inflammatory background (Fig. 1A ,B), which was lymphoplasmacytic in 6 cases and neutrophilic in 3 cases (including 1 case rich in both lymphocytes and neutrophils); an eosinophilic background was absent. Background necrosis was noted in 2 cases (25%). Of the 6 cases with available air-dried smears, 3 (50%) showed the presence of lymphoglandular bodies (Fig. 1C) . A prominent vasculature was noted in 1 case. The tumor cells, often admixed with inflammatory cells, were characteristically epithelioid in 7 cases (88%) and occasionally spindly in 3 cases (38%). Of the 8 cases, 7 (88%) showed foamy vacuolated cytoplasm (Fig. 1B,F) , and 6 (75%) demonstrated voluminous cytoplasm with a tumor size more than 20 times greater than that of a red blood cell (Fig. 1F) . Cytophagocytosis was present in 4 cases (50%): 2 cases in 1 patient demonstrated hemophagocytosis, as illustrated by digested erythrocytes within the cytoplasm of the tumor cells (Fig. 1G) , and emperipolesis, with intact lymphocytes or plasma cells present within the cytoplasm of the tumor cells (Fig. 1H,I ).
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Hemophagocytosis and emperipolesis were also noted in 1 additional case each and were thus present in 3 of 8 cases (38%). A wide spectrum of nuclear morphology was present; it ranged from reniform or donut-shaped configurations to notable multilobation, multinucleation, and bizarre configurations. Reniform or donut-shaped nuclei with irregular nuclear contours (Fig. 1B,C 1D ,F) along with binucleated histiocytoid tumor cells with abundant eosinophilic cytoplasm and ovoid-to-oblong, partially overlapping, eccentrically placed nuclei resembling Pac-Man (Fig. 1C ). In addition, there was a wide range of nuclear sizes: it ranged 5 to 20 times greater than the size of a red blood cell in 7 cases (88%), and there were even larger, massive single nuclei (Fig. 1E ) that were more than 20 times greater than the size of a red blood cell in 3 cases (38%). Vesicular chromatin and conspicuous nucleoli were common and noted in 7 (88%) and 5 cases (63%), respectively. Intranuclear inclusion was present in only 1 case (13%), and nuclear grooves were absent. Mitoses were seen in 5 cases (63%), although atypical mitoses were present in only 1 case (13%).
Histologic Features
Histologic sections of core-needle biopsy specimens (cases 1, 2, 4A, 4B, and 5B) and an excisional biopsy specimen (case 6) were reviewed along with 2 subsequent surgical resections (lobectomy and adrenalectomy/nephrectomy) from case 1, a hysterectomy from case 3, and a scapular mass resection from case 4. Regardless of the pretreatment status, all HS cases were histologically similar and were predominantly characterized by a diffuse or vaguely nodular infiltrative pattern. Large, atypical epithelioid, pleomorphic, or histiocytoid cells were present in a lymphocytic or lymphoplasmacytic background, occasionally with a neutrophilic component ( Fig. 2A) . Variable hemorrhage and necrosis were present along with mitoses, including atypical forms. Though evident in 3 FNA cytology cases, cytophagocytosis was difficult to identify in the core biopsies or subsequent resections. The neoplastic cells appeared variable in size, which ranged from moderate to large, and diverse in architectural arrangement: discohesive, cohesive, or even syncytial with indistinct cell borders. A prominent histologic feature was extreme nuclear pleomorphism, both within a given case and among the cases: The nuclei ranged from ovoid or reniform to multilobated or bizarre and adopted an embryo-like or Reed Sternberg-like configuration (Fig. 2B) . Multinucleation with vesicular chromatin, conspicuous-to-prominent nucleoli, and well-demarcated nuclear membranes were often noted. 
Immunohistochemical Findings
Cytoplasmic immunoreactivity for histiocytic markers CD68 and CD163 was observed in 86% and 100% of the cases tested, respectively, although the staining intensity was heterogeneous (Fig. 2C) . Nuclear immunoreactivity for PU.1 (Fig. 2D ) was present in 3 of the 4 tested cases (75%). Five of the 6 cases (83%) tested for more than 1 histiocytic marker (CD68, CD163, and PU.1) showed positivity for at least 2 markers. In fact, 2 cases showed positivity for all 3 markers: CD68, CD163, and PU.1.
The 1 remaining case (case 6) showed negativity for CD68 but positivity for PU.1, CD4, and CD31. Lysozyme reactivity was noted in only 1 of 3 cases tested (33%). Immunoreactivity for CD31, CD4, and leukocyte common antigen (CD45) was present in 50%, 80%, and 80% of cases tested, respectively. Focal and weak S100 protein staining was noted in 3 of 7 cases (43%). All tested cases were negative for cytokeratins, melanocytic markers (MART-1 and HMB45), lymphoma markers (CD3, CD20, PAX5, and ALK-1), markers of various common sarcomas (CD34, desmin, ERG, MDM2, and CDK4), dendritic cell markers (CD21), and Langerhans cell markers (CD1a and langerin). The number of markers used for the diagnosis of HS in our series ranged from 4 to 6 (mean, 5) in recurrent/metastatic cases and up to 19 to 27 (mean, 22) in cases for a primary diagnosis. Table 3 summarizes molecular findings from 5 cases in our cohort along with targeted-exome NGS data from 4 cases. For the sequencing of 3 cases (1, 4A/4B, and 6) performed at our institution, the estimated percentage of tumor cells in the specimen was approximately 80%; the mean coverage ranged from 220 to 276 reads across all targeted exons, with 94% to 98% of all exons having more than 30 reads. Two cases (1 and 3) demonstrated IGH clonality. IGH-BCL2 translocation was present in 2 patients (1 and 4A/ 4B), whereas a CCND1-IGH translocation was present in 1 patient (case 3) as documented previously. 7 Recurrent alterations in KMT2D/MLL2, which encode the MLL/ SET1 class of histone lysine methyltransferases, were present in 3 cases (Fig. 3) , with KMT2D/MLL2 mutations present in a significant fraction of sequencing reads (12%-45%). Remarkably, case 6 harbored a reciprocal internal rearrangement involving KMT2D on 12q13.2 and KDM2B on 12q24.31, with a copy-number analysis showing a complex karyotype (deletion of 1p, 3p, 5q, 10q, 11p, 13q, 16p, and 16q and amplification of 3q, 12p, and 15q). The 1 remaining case (case 2) showed alterations in other chromatin-modifying enzymes, including DNMT3A and KDM4C. Amplification of 9p24, including the CD274 and PDCDLG2 (PDL1/L2) loci, was present in 1 case (4A/4B).
Molecular Characterization
DISCUSSION
HS is a difficult diagnosis that may be unrecognized or misdiagnosed in FNA samples because of its rarity, its overlapping morphology with various neoplasms, and the lack of a distinctive cytomorphologic description in the textbooks or literature. Clinically, HS often presents in extranodal sites and pursues an aggressive clinical course. Of the large case series of extranodal HS by Hornick et al, 9 half were from an extremity or buttock, with the remainder from the gastrointestinal tract, head and neck, and lungs. In our cohort and the prior FNA case reports, 11-16 the presentation was predominantly in the head and neck region (5 cases and 5 patients), which was followed by the retroperitoneum (5 cases and 4 patients) and lungs (2 cases and 2 patients). These sites, especially the head and neck, are superficial and amenable to sampling by FNA. Because of its aggressive nature, the importance of diagnosing HS by FNA in a timely fashion cannot be understated. Recognizing HS by FNA alone, however, is extremely challenging if not impossible, particularly at the initial presentation; this is reflected by the fact that HS was not recognized in all the FNA cases reported previously [11] [12] [13] [14] [15] [16] and in 2 of 5 cases in our cohort. HS was correctly diagnosed in 2 cases with concurrent core-needle biopsies (cases 4A and 5B) and was listed as one of the many differential diagnoses in 1 case 
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(case 6). In addition, misdiagnoses were not uncommon, particularly in locations where carcinomas and lymphomas were far more commonly seen. A lung HS in our cohort was initially misinterpreted as "suspicious for non-small cell carcinoma," and a neck mass in a previous cytology case report was called "poorly differentiated carcinoma or lymphoma." 14 Nevertheless, in all 3 cases with a prior history of HS, the correct diagnosis was reached with FNA cytology; thus, HS is recognizable on FNA if it is under consideration as one of the diagnoses. In 2003, Miliauskas 11 described the first case of HS sampled cytologically: large pleomorphic cells with occasional reniform nuclei, prominent nucleoli, and moderately dense and abundant vacuolar cytoplasm in a lymphohistiocytic background. Similar findings were described in the 3 subsequent reports 13, 14, 16 ; notably, Singh et al 16 (Table 2) : voluminous cytoplasm with a giant nucleus (more than 20 times larger than the size of a red blood cell; Fig. 1F ), a monster-like nucleus (multilobulated giant nucleus; Fig.  1D ), and Pac-Man-like nuclei (Fig. 1C) . Furthermore, we have found that lymphoglandular bodies and cytophagocytosis are 2 diagnostic clues to HS in otherwise nonspecific smears with a pleomorphic, large epithelioid cell pattern. Interestingly, these useful diagnostic clues are more prominent on FNA smears than histologic sections; on the latter, a dense inflammatory infiltrate may mask cytophagocytosis. A constellation of these features may be helpful in suggesting and even favoring the diagnosis of HS amid a lengthy list of alternative diagnoses.
Immunohistochemistry is integral to the diagnosis of HS both to confirm histiocytic differentiation in tumor cells and to exclude other poorly differentiated epithelioid neoplasms, including large cell lymphomas, carcinomas, melanomas, and certain sarcomas. Many immunohistochemical markers once thought to be specific for histiocytic differentiation, such as a-1-antitrypsin, lysozyme, and CD68, have been shown to have low specificity. 10 For instance, lysozyme can be expressed in a variety of nonHodgkin lymphomas, and CD68 can be expressed in a large subset of melanomas. 25 CD163, recently noted as an immunohistochemical marker for the histiocytic lineage, 26 appears to be more specific than CD68 and is useful for establishing the diagnosis of HS. 10 PU.1, a macrophage and B-cell transcription factor, has recently been used as a nuclear marker for histiocytes and for the diagnosis of HS. 8 Consistent with these reports, the sensitivity of CD68, CD163, and PU.1 in our cohort was 86%, 100%, and 75%, respectively, and this highlights their utility in confirming the histiocytic lineage; in fact, 83% of our cases showed immunopositivity for at least 2 of these 3 markers.
As demonstrated by Hornick et al, 9 immunoreactivity for CD31, a vascular marker with known cross-reactivity in macrophages, 27 could be an additional diagnostic clue (or pitfall) for HS during a workup of an epithelioid tumor. Because of the extremely broad differential diagnosis of HS in the initial diagnosis, a panel of additional immunohistochemical markers would be needed to exclude poorly differentiated carcinomas (cytokeratins), melanomas (Sox10, HMB45, and Mart-1), large cell lymphomas (CD3, CD20, CD30, PAX5, and ALK-1), sarcomas with a dominant epithelioid morphology (CD34, CD31, desmin, ERG), and dendritic and Langerhans cell neoplasms (CD21, CD35, langerin, and CD1a). The numbers of immunostains performed for the initial diagnosis of HS, not reported before in the literature, was, therefore, high as expected (up to 27 in our cohort). Because of the limited quantity of diagnostic material available for ancillary studies in most needle biopsy specimens and the changing reimbursement landscape for immunohistochemistry, a more focused workup is highly desired. This could be potentially achieved if we suspect HS on FNA smears with a mixed large epithelioid cell and inflammatory pattern and notice lymphoglandular bodies, cytophagocytosis, and large histiocytoid cells with Pac-Man-like nuclei. The histogenesis of HS and its relation with other hematolymphoid and dendritic cell neoplasms remain active areas of investigation. According to the WHO classification, HS belongs to the group of histiocytic and dendritic cell neoplasms, 1,2 which encompasses those with a myeloid-derived histiocytic origin (HS), a myeloid-derived ; it is intriguing to speculate that histiocytes, an extremely common component of cystic fluids and body fluids, may originate from another lineage of cells, such as mesothelial cells, via transdifferentiation. In our series, 4 of 6 HS patients had a history of hematolymphoid malignancy: low-grade FL, blastoid mantle cell lymphoma, and multiple myeloma. Currently, the mechanism of transdifferentiation from neoplastic lymphoid cells into HS is unknown.
Targeted-exome NGS of HS in our series revealed recurrent alterations in KMT2D/MLL2 on chromosome 12q13.2, a gene involved in chromatin regulation by encoding the MLL/SET1 class of histone lysine methyltransferases. Somatic mutations of KMT2D/MLL2 have been reported in hematologic malignancies such as acute myeloid leukemia and solid tumors such as lung, large intestine, and endometrial carcinomas. 30 
KMT2D/MLL2
inactivation has been shown to be a driver event in the pathogenesis of FL 31 by perturbing germinal center B-cell development. For the 3 cases with KMT2D/MLL2 perturbation, 2 patients had a known history of low-grade FL, which has been reported to harbor KMT2D/MLL2 alterations. Nonetheless, the substantial fraction of altered KMT2D/MLL2 transcripts detected in the tumor would argue against contamination from preexisting lymphoma cells and instead suggest that KMT2D/MLL2 alterations were indeed present in the HS tumor cells, although no lymphoma samples were available for matched molecular testing in our cases. The presence of recurrent KMT2D/ MLL2 alterations implicates chromatin dysregulation in the pathogenesis of HS, and because of their role in the pathogenesis of FL, this is consistent with a model in which HS could originate from transdifferentiation of a low-grade FL with preexisting KMT2D/MLL2 alterations. In addition to KMT2D/MLL2, alterations in chromatin-modifying enzymes such as DNMT3A and KDM4C were noted in 1 additional case in our series, and this further supports the role of epigenetic regulation in the pathogenesis of HS. Interestingly, the BRAF V600E mutation, which has been reported in various more indolent histiocytic and dendritic cell neoplasms/lesions, including Langerhans cell histiocytosis, follicular dendritic cell sarcoma, disseminated juvenile xanthogranuloma, and Erdheim-Chester disease, 32 was not detected in our cohort. This report, to the best of our knowledge, represents the largest series of HS sampled by FNA. Diagnosing HS with FNA cytology alone is extremely challenging on initial presentation but is straightforward on recurrence. A presumptive diagnosis of HS and judicious use of histiocytic lineage markers may follow after the recognition of key cytologic features: large epithelioid tumor cells with pronounced nuclear pleomorphism, multinucleation, voluminous/vacuolated cytoplasm, and reniform or Pac-Man-like nuclei in an inflammatory background with lymphoglandular bodies and cytophagocytosis. Our study also demonstrates for the first time that HS harbors recurrent alterations in KMT2D/MLL2, a gene involved in chromatin modulation and implicated in lymphomagenesis, and it thus links epigenetic regulation to the pathogenesis of HS. Our observations may also shed some light on our understanding of the origin of histiocytes, one of the most common cell types in cytology.
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